OXACILLIN SODIUM

Post-LOE

oxacillin sodium

Novartis

ANDAINJECTIONINJECTABLE

Approved

Apr 1971

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

OXACILLIN SODIUM (oxacillin sodium) by Novartis is clinical pharmacology intravenous administration provides peak serum levels approximately 5 minutes after the injection is completed. Approved for the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. First approved in 1971.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Intravenous administration provides peak serum levels approximately 5 minutes after the injection is completed. Slow I.V. administration of 500 mg gives a peak serum level of 43 mcg/mL after 5 minutes with a half-life of 20 to 30 minutes. Oxacillin sodium, with normal doses,…

Worked on OXACILLIN SODIUM at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

OXACILLIN SODIUM

Mechanism of Action

Indications (1)